Werner Poewe

Aug 13, 2024 | emjreviews.com | Werner Poewe

INTRODUCTION Parkinson’s disease (PD) is the second-most common neurodegenerative disease after Alzheimer’s disease (AD), with an estimated 6.1 million people affected worldwide.1 PD is also the fastest-growing neurodegenerative disorder, with an expected two-fold increase in prevalence over the next generation.1,2 The pathological hallmark of both PD and the overlapping condition of dementia with Lewy bodies (DLB) is the presence of intraneuronal and axonal inclusions, called Lewy bodies and...

Jul 4, 2024 | movementdisorders.onlinelibrary.wiley.com | Werner Poewe |Horacio Kaufmann |Niall Quinn

OBITUARY In Memoriam Gregor K.

Jul 26, 2023 | onlinelibrary.wiley.com | Werner Poewe

Abstract Adjunct therapy with the COMT-inhibitor entacapone is a first line approach to treat wearing-off type motor fluctuations in levodopa-treated PD patients. Five randomised placebo-controlled trials including a total of more than 1,000 patients have established its efficacy showing increases in ON-time between 0.7 to 1.6 hours with corresponding OFF-time reductions. These and other trials also found improvements in ON-motor function and quality of life.